DK1181038T3 - Hidtil ukendte indikationer af mannanbindende lectin (MBL) til behandling af immunkompromitterede individer - Google Patents

Hidtil ukendte indikationer af mannanbindende lectin (MBL) til behandling af immunkompromitterede individer

Info

Publication number
DK1181038T3
DK1181038T3 DK00925098T DK00925098T DK1181038T3 DK 1181038 T3 DK1181038 T3 DK 1181038T3 DK 00925098 T DK00925098 T DK 00925098T DK 00925098 T DK00925098 T DK 00925098T DK 1181038 T3 DK1181038 T3 DK 1181038T3
Authority
DK
Denmark
Prior art keywords
treatment
mbl
mannan
prophylaxis
binding lectin
Prior art date
Application number
DK00925098T
Other languages
Danish (da)
English (en)
Inventor
Jens Christian Jensenius
Steffen Thiel
Original Assignee
Steffen Thiel
Jens Christian Jensenius
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steffen Thiel, Jens Christian Jensenius filed Critical Steffen Thiel
Application granted granted Critical
Publication of DK1181038T3 publication Critical patent/DK1181038T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Filtering Materials (AREA)
  • Wrappers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
DK00925098T 1999-05-14 2000-05-10 Hidtil ukendte indikationer af mannanbindende lectin (MBL) til behandling af immunkompromitterede individer DK1181038T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900668 1999-05-14
DKPA199901508 1999-10-20
EP00925098A EP1181038B1 (de) 1999-05-14 2000-05-10 Neue indikationen für mannan-binding lectin (mbl) zur behandlung von immungeschwächten patienten

Publications (1)

Publication Number Publication Date
DK1181038T3 true DK1181038T3 (da) 2004-08-09

Family

ID=26064419

Family Applications (3)

Application Number Title Priority Date Filing Date
DK03029993T DK1402897T3 (da) 1999-05-14 2000-05-10 Hidtil ukendte indikationer af mannanbindende lectin (MBL) til behandling af immunkompromitterede individer
DK00925098T DK1181038T3 (da) 1999-05-14 2000-05-10 Hidtil ukendte indikationer af mannanbindende lectin (MBL) til behandling af immunkompromitterede individer
DK00925097T DK1181363T3 (da) 1999-05-14 2000-05-10 Rekombinant humant mannanbindende lectin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK03029993T DK1402897T3 (da) 1999-05-14 2000-05-10 Hidtil ukendte indikationer af mannanbindende lectin (MBL) til behandling af immunkompromitterede individer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK00925097T DK1181363T3 (da) 1999-05-14 2000-05-10 Rekombinant humant mannanbindende lectin

Country Status (15)

Country Link
US (5) US6562784B1 (de)
EP (3) EP1181038B1 (de)
JP (2) JP2002544286A (de)
CN (2) CN1359298A (de)
AT (3) ATE336260T1 (de)
AU (2) AU779404B2 (de)
CA (2) CA2372435A1 (de)
DE (3) DE60033147T2 (de)
DK (3) DK1402897T3 (de)
ES (3) ES2281341T3 (de)
NO (2) NO20015481L (de)
NZ (2) NZ515717A (de)
PT (3) PT1181363E (de)
RU (2) RU2292217C2 (de)
WO (2) WO2000069894A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
ES2281341T3 (es) * 1999-05-14 2007-10-01 Steffen Thiel Lectina humana recombinante que se une a manano.
WO2002005833A1 (en) * 2000-07-13 2002-01-24 Natimmune A/S MANNAN-BINDING LECTIN (MBL) TREATMENT OF INFECTIONS IN INDIVIDUALS TREATED WITH TNF-αinhibitors
EP1186299A1 (de) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht Diagnose, Verbeugung und/oder Behandlung von Atherosklerose, Infectionen und Störungen des Immunsystems
US20040043034A1 (en) * 2000-11-27 2004-03-04 Jensenius Jens Christian Collectins as adjuvants
WO2003010188A1 (en) 2001-07-23 2003-02-06 Natimmune A/S Production of high molecular mass lectins
JP4051030B2 (ja) * 2001-08-31 2008-02-20 扶桑薬品工業株式会社 ヒトマンノース結合レクチンの精製方法、ヒトマンノース結合レクチン組成物およびヒトマンノース結合レクチンの医薬用途
EP1335932B1 (de) * 2001-10-19 2005-11-30 Natimmune A/S Isolierung von lectinen
CN1652813A (zh) * 2002-03-15 2005-08-10 纳蒂芒公司 包含甘露糖结合凝集素的药用组合物
US7211396B2 (en) 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin
JP2005523336A (ja) * 2002-04-24 2005-08-04 ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ マンノース結合レクチン及びその使用方法
US20050123899A1 (en) * 2002-06-28 2005-06-09 Nobutaka Wakamiya Anti-hiv agent
DK1539964T3 (da) * 2002-09-10 2007-05-07 Natimmune As Cellectin-komplementaktiverende proteinkimærer
GB0222014D0 (en) * 2002-09-23 2002-10-30 Leuven K U Res & Dev Mannan-binding lectin
CA2516403C (en) * 2003-01-17 2014-08-12 Aethlon Medical, Inc. Method for removal of viruses from blood by lectin affinity hemodialysis
PT2374819T (pt) 2003-05-12 2017-07-04 Helion Biotech Aps Anticorpos para masp-2
US7135338B2 (en) * 2003-06-11 2006-11-14 Dobeel Corporation Methods for overexpression of high molecular weight form of mannose binding lectin (MBL) and a specific formulation for active treatment for systemic infection with microorganism
DE20317914U1 (de) 2003-11-19 2004-12-30 Weh, Erwin Betätigungsvorrichtung für eine Schnellanschlusskupplung
US7335633B2 (en) 2004-01-12 2008-02-26 Cornell Research Foundation, Inc. Detecting recurrent vulvovaginal candidiasis or vulvar vestibulitis syndrome and method for treating same
WO2005080594A2 (en) * 2004-02-24 2005-09-01 Innogenetics N.V. Method for determining the risk of developing a neurological disease
US7964559B2 (en) 2004-03-09 2011-06-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services MVL, an antiviral protein from a cyanobacterium
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP1618887A1 (de) * 2004-07-12 2006-01-25 UMC Utrecht Holding B.V. Beseitigung von Polyolen aus dem Körper
EP1797197A1 (de) * 2004-09-29 2007-06-20 Mellitus S.L. Verfahren zur detektion einer prädisposition für schwangerschaftsdiabetes sowie zur behandlung dieser krankheit
DE602005026705D1 (de) * 2004-12-23 2011-04-14 Council Scient Ind Res Pharmazeutische zusammensetzung zur behandlung von invasiver lungenaspergillose
CN101094651B (zh) * 2004-12-30 2011-03-09 多贝尔有限公司 含有胶原凝集素家族蛋白质或者其变体的喷雾干燥的组合物和其制备方法
CN101193651A (zh) * 2005-04-11 2008-06-04 内蒂穆恩公司 甘露聚糖结合凝集素(mbl)在治疗与癌症相关的免疫削弱的病症中的用途
US9220831B2 (en) 2005-10-06 2015-12-29 Children's Medical Center Corporation Device and method for combined microfluidic-micromagnetic separation of material in continuous flow
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
WO2007085057A1 (en) * 2006-01-25 2007-08-02 The Council Of The Queensland Institute Of Medical Research A medical protocol
US20070226567A1 (en) * 2006-03-23 2007-09-27 Gorman Kevin W High speed bist utilizing clock multiplication
US20110052428A1 (en) * 2008-01-16 2011-03-03 Superpar Otomotiv Sanayi Ve Ticaret Anonim Sirketi Electric fuel pump for heavy duty engine platforms
US20100331240A1 (en) * 2008-01-18 2010-12-30 The General Hospital Corporation Methods for prevention and treatment of infections with supraphysiological doses of mannan-binding lectin (mbl) and ficolin-mbl fusion proteins
WO2010123594A2 (en) 2009-01-15 2010-10-28 Children's Medical Center Corporation Device for filtration of fluids there through and accompanying method
DK2526119T3 (en) * 2010-01-19 2018-07-30 Harvard College Manipulated opsonin for pathogen detection and treatment
WO2011100528A2 (en) * 2010-02-12 2011-08-18 Emory University Compositions and uses of lectins
DE102011003478A1 (de) * 2011-02-01 2012-08-02 Cytavis Biopharma Gmbh Antivirales Mittel enthaltend rekombinante Mistellektine
CA2842321C (en) 2011-07-18 2022-05-03 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
AU2013225823A1 (en) 2012-02-29 2014-09-18 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
US20150173883A1 (en) 2012-07-18 2015-06-25 President And Fellows Of Harvard College Modification of surfaces for simultaneous repellency and targeted binding of desired moieties
EP2976642A4 (de) 2013-03-15 2016-09-21 Harvard College Verfahren und zusammensetzungen zur verbesserung der erkennung und/oder aufnahme einer zieleinheit
AU2014268603B2 (en) 2013-05-21 2018-03-22 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
EP3083658B1 (de) 2013-12-18 2019-05-08 President and Fellows of Harvard College Detektion gram-positiver bakterien mit crp
WO2016077067A2 (en) * 2014-10-27 2016-05-19 President And Fellows Of Harvard College Magnetic capture of a target from a fluid
EP3331549B1 (de) 2015-08-06 2020-12-23 President and Fellows of Harvard College Verbesserte mikrobenbindende moleküle und verwendungen davon
EP3458483A1 (de) 2016-05-16 2019-03-27 President and Fellows of Harvard College Wässriges biomolekül mit kopplung an co2-plasma-aktivierte oberflächen
CN107050427A (zh) * 2017-02-27 2017-08-18 新乡医学院 MBL在制备预防或治疗以Tregs为靶点的疾病药物中的应用
CN107050436B (zh) * 2017-02-27 2020-03-17 新乡医学院 Mbl在制备预防或治疗效应t细胞引发疾病药物中的应用
WO2019110706A1 (en) * 2017-12-08 2019-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of developing a sepsis or a systemic inflammatory response syndrome (sirs)
RU2739113C1 (ru) * 2019-10-04 2020-12-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр терапии и профилактической медицины" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ТПМ" Минздрава России) Способ определения активности маннан-связывающих лектин-ассоциированных сериновых протеаз в тесте коагуляции фибриногена
WO2023087090A1 (en) * 2021-11-18 2023-05-25 Magellan Therapeutics Inc. Recombinant proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001519A1 (en) * 1987-08-20 1989-02-23 Children's Hospital Corporation Human mannose binding protein
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
US5112952A (en) 1990-09-28 1992-05-12 Pierce Chemical Company Composition and method for isolation and purification of Immunoglobulin M
EP0856580A4 (de) 1995-08-17 2001-02-07 Fuso Pharmaceutical Ind Rekombinantes conglutinin und verfahren zu dessen herstellung
AU8748198A (en) 1997-08-21 1999-03-16 Takara Shuzo Co., Ltd. Carcinostatic agents
WO1999064453A1 (en) 1998-06-10 1999-12-16 Statens Serum Institut Purification process for production of mannan-binding lectin and an mbl medicinal product
ES2281341T3 (es) * 1999-05-14 2007-10-01 Steffen Thiel Lectina humana recombinante que se une a manano.

Also Published As

Publication number Publication date
US6562784B1 (en) 2003-05-13
NO20015506L (no) 2002-01-09
WO2000070043A1 (en) 2000-11-23
ES2271468T3 (es) 2007-04-16
RU2292217C2 (ru) 2007-01-27
AU4393600A (en) 2000-12-05
AU4393500A (en) 2000-12-05
DE60009896D1 (de) 2004-05-19
US20040229212A1 (en) 2004-11-18
ES2219336T3 (es) 2004-12-01
NZ515717A (en) 2004-01-30
PT1181363E (pt) 2007-05-31
CA2372128A1 (en) 2000-11-23
DE60033147D1 (de) 2007-03-15
CN1359420A (zh) 2002-07-17
DK1181363T3 (da) 2007-05-29
EP1402897B1 (de) 2006-08-16
NO20015506D0 (no) 2001-11-09
JP2002543837A (ja) 2002-12-24
US7202207B2 (en) 2007-04-10
NO20015481L (no) 2002-01-11
US6846649B1 (en) 2005-01-25
EP1181038B1 (de) 2004-04-14
AU781135B2 (en) 2005-05-05
CA2372435A1 (en) 2000-11-23
WO2000069894A2 (en) 2000-11-23
WO2000069894A3 (en) 2001-02-08
NZ515718A (en) 2004-03-26
ATE352620T1 (de) 2007-02-15
ES2281341T3 (es) 2007-10-01
DE60030173T2 (de) 2007-08-23
EP1181363B1 (de) 2007-01-24
DE60009896T2 (de) 2005-04-21
AU779404B2 (en) 2005-01-20
DE60033147T2 (de) 2007-12-13
US20070197428A1 (en) 2007-08-23
EP1181038A2 (de) 2002-02-27
RU2005125625A (ru) 2007-02-20
US7439224B2 (en) 2008-10-21
NO20015481D0 (no) 2001-11-08
US20030191052A1 (en) 2003-10-09
EP1402897A3 (de) 2004-06-30
JP2002544286A (ja) 2002-12-24
EP1181363A1 (de) 2002-02-27
CN1359298A (zh) 2002-07-17
EP1402897A2 (de) 2004-03-31
DK1402897T3 (da) 2006-12-27
PT1402897E (pt) 2007-01-31
DE60030173D1 (de) 2006-09-28
ATE264111T1 (de) 2004-04-15
PT1181038E (pt) 2004-08-31
ATE336260T1 (de) 2006-09-15

Similar Documents

Publication Publication Date Title
DK1402897T3 (da) Hidtil ukendte indikationer af mannanbindende lectin (MBL) til behandling af immunkompromitterede individer
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
SE0102315D0 (sv) Compounds
MA27998A1 (fr) Nouvelle formulation
HUP0103889A2 (hu) Kopolimer-1-rokon polipeptidek alkalmazása molekulatömeg kalibráló standardként és gyógyászati anyagként
MY106315A (en) Pharmaceutical agents
HUP9903759A2 (hu) Mikrobaellenes készítmények
HUP0300725A2 (hu) Az inzulinrezisztencia-szindróma kezelése CGMP PDE5 inhibitorokkal
ATE291424T1 (de) Katechin und quercetin zur pharmazeutischen oder diätetischen verwendung
YU13301A (sh) Muskarinski agonisti i antagonisti
ATE407947T1 (de) Proteine mit il-6 inhibitorischer wirkung
DE60025026D1 (de) Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins
YU39598A (sh) Upotreba duloksetina i njegova farmaceutska smeša
NO20032597L (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
FR2710844B1 (fr) Composition pour le traitement ou la prévention de l'herpès.
NZ228068A (en) Brominated or chlorinated allylamines and their pharmaceutical compositions
ATE241640T1 (de) Fusidinsäure-derivate
EP1370697A4 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion und verfahren zu deren verwendung
FR2823207B1 (fr) Complexes d'anilides a chaine polycarbonee et de cyclodestrines, leur preparation et leur application en tant que medicamment en particulier pour le traitement des dislipidemies
MXPA04006120A (es) Piperidin-2,6-dionas sustitudas heterociclicamente en posicion 3.
WO2002097075A3 (en) Capping enzyme of flavivirus and utilization of this protein in a process to test drugs with antiviral properties
HUP0402645A2 (hu) Egy glitazont és egy 4-oxobutánsavat tartalmazó gyógyászati készítmény és ennek alkalmazása cukorbetegség kezelésére
ES2127133A1 (es) Utilizacion de derivados 2,5-dihidroxibencenosulfonicos para la fabricacion de medicamentos destinados al tratamiento y a la prevencion de la enfermedad de alzheimer.
PT1355650E (pt) Combinacao de ingredientes activos contendo alfuzosina e apomorfina
WO2002055068A3 (fr) Cystine par voie orale pour traiter l'oeil sec